Eirik Søfteland

Prof. Eirik Søfteland

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Diabetes Care
Verified
Journal Article
Open access
PDF file
ESEirik Søfteland
Eirik Søfteland
JMJuris J. Meier
Juris J. Meier
BVBente Vangen
Bente Vangen
RTRobert Toorawa
Robert Toorawa
MMMario Maldonado-Lutomirsky
Mario Maldonado-Lutomirsky
UBUli C. Broedl
Uli C. Broedl
OBJECTIVE: To evaluate the efficacy and safety of empagliflozin versus placebo as add-on therapy in patients with type 2 diabetes and inadequate glycemic control with linagliptin and metformin. RESEARCH DESIGN AND METHODS: Patients with HbA1c ≥8.0% and ≤10.5% (≥64 and ≤91 mmol/mol) while receiving stable-dose metformin received open-label linagliptin 5 mg (n = 606) for 16 weeks. Subsequently, those with HbA1c ≥7.0 and ≤10.5% (≥53 and ≤91 mmol/mol) were randomized to receive double-blind, double-dummy treatment with empagliflozin 10 mg (n = 112), empagliflozin 25 mg (n = 111), or placebo (n = 110) for 24 weeks; all patients continued treatment with metformin and linagliptin 5 mg. The primary end point was the change from baseline in HbA1c after 24 weeks of double-blind treatment. RESULTS: At week 24, empagliflozin significantly reduced HbA1c (mean baseline 7.96–7.97% [63–64 mmol/mol]) versus placebo; the adjusted mean differences in the change from baseline with empagliflozin 10 and 25 mg versus placebo were −0.79% (95% CI ‒1.02, ‒0.55) (−8.63 mmol/mol [‒11.20, ‒6.07 mmol/mol]) and −0.70% (95% CI ‒0.93, ‒0.46) (−7.61 mmol/mol [‒10.18, ‒5.05 mmol/mol]), respectively (both P < 0.001). Fasting plasma glucose and weight were significantly reduced in both empagliflozin groups versus placebo (P < 0.001 for all comparisons). More patients receiving placebo than empagliflozin 10 and 25 mg reported adverse events during double-blind treatment (68.2%, 55.4%, and 51.8%, respectively). CONCLUSIONS: Empagliflozin treatment for 24 weeks improved glycemic control and weight versus placebo as an add-on to linagliptin 5 mg and metformin and was well tolerated.

30 April 2015 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
CTCharalampos Tzoulis
Charalampos Tzoulis
TSThomas Schwarzlmüller
Thomas Schwarzlmüller
IGIvar Otto Gjerde
Ivar Otto Gjerde
ESEirik Søfteland
Eirik Søfteland
GNGesche Neckelmann
Gesche Neckelmann
OVOlav Karsten Vintermyr
Olav Karsten Vintermyr
Erdheim-Chester disease is a rare histiocytosis characterized by multi-systemic organ involvement. Immune-modulating agents such as interferon-alpha have limited success and the disorder is progressive and causes high morbidity and mortality. Treatment with the BRAF-inhibitor vemurafenib has recently produced substantial improvement in three patients with Erdheim-Chester disease expressing the p. V600E BRAF mutation. The disorder commonly affects the central nervous system and it is not yet known whether vemurafenib can reverse intra-axial infiltration and the resulting neurological impairment. In this work, we report for the first time an excellent clinical response to vemurafenib in a Norwegian patient with debilitating progressive spastic paraparesis due to intra-axial infiltration of the thoracic spinal cord. The patient had been unresponsive to interferon-alpha. Low dose vemurafenib (720 mg daily) for a period of three months resulted in significant tumor shrinkage by >60% and regression of contrast enhancement and fluorodeoxyglucose uptake on positron-emission tomography. The patient’s spastic paraparesis and gait function improved dramatically. She currently walks unaided and reports a substantially improved quality of life. Our findings show that vemurafenib therapy, even at low doses, can be effective for the treatment of intra-axial central nervous system involvement in BRAF-positive Erdheim-Chester disease.

1 May 2014 in Journal of Diabetes and its Complications
Verified
Journal Article
Open access
ESEirik Søfteland
Eirik Søfteland
CBChristina Brock
Christina Brock
JFJens Brøndum Frøkjær
Jens Brøndum Frøkjær
Jan BroggerJan Brogger
Jan Brogger
LMLászló Madácsy
László Madácsy
GDGeorg Dimcevski
Georg Dimcevski
Gastrointestinal complaints are common in diabetes mellitus. However, its association to peripheral sensorimotor and autonomic neuropathies is not well investigated. The aim was to assess skin, muscle, bone and visceral sensitivity in diabetes patients with sensorimotor neuropathy, and correlate these with gastrointestinal symptoms and degree of cardiac autonomic neuropathy. Twenty patients with sensorimotor neuropathy (65% type 2 diabetes, aged 58.3±12.0 years, diabetes duration 15.8±10.0 years) and 16 healthy controls were recruited. Cutaneous sensitivity to von Frey filaments, mechanical allodynia, muscle/bone/rectosigmoid sensitivities, and heart rate variability were examined. Gastrointestinal symptom scores (PAGI-SYM) and health-related quality of life (SF-36) were also recorded. Patients displayed hypesthesia to von Frey filaments (p=0.028), but no difference to muscle and bone pain sensitivities. Also, patients were hyposensitive to multimodal rectal stimulations (all p<0.05), although they suffered more gastrointestinal complaints. Heart rate variability was reduced in the patient cohort. Rectal mechanical and cutaneous sensitivities correlated (p<0.001), and both were associated with heart rate variability as well as PAGI-SYM and SF-36 scores (p<0.01). In diabetic sensorimotor neuropathy there is substantial evidence of concomitant cutaneous, cardiac and visceral autonomic neuropathies. The neuropathy may reduce quality of life and explain the higher prevalence of gastrointestinal complaints.

1 October 2019 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
ESEirik Søfteland
Eirik Søfteland
JPJakob Lykke Poulsen
Jakob Lykke Poulsen
JSJakob Starup-Linde
Jakob Starup-Linde
TCTrine Tang Christensen
Trine Tang Christensen
SOSøren Schou Olesen
Søren Schou Olesen
GDGeorg Dimcevski
Georg Dimcevski

23 October 2021 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
DSDag A. Sangnes
Dag A. Sangnes
KLKatarina Lundervold
Katarina Lundervold
MBMattis Bekkelund
Mattis Bekkelund
HVHilde L. von Volkmann
Hilde L. von Volkmann
BBBirgitte Berentsen
Birgitte Berentsen
ESEirik Søfteland
Eirik Søfteland
Background: Diabetic constipation is traditionally attributed to slow colonic transit, despite limited evidence. More than half of patients find treatment unsatisfactory. To improve treatment, there is a need for better diagnostic understanding of the condition.Objective: In this wireless motility capsule study, we aimed to investigate gastrointestinal transit and contractility in diabetes patients with and without constipation, and in healthy controls.Methods: We prospectively included type 1 or type 2 diabetes patients with gastrointestinal symptoms. Based on the Gastrointestinal Symptom Rating Scale we distinguished into two groups: with constipation and without constipation. Non‐diabetic controls were asymptomatic. All were examined with wireless motility capsule, determining transit times and contractility parameters.Results: 57 patients (42 women, 46 with type 1 diabetes) and 26 healthy controls (14 women) were included. We found no difference in transit times between diabetes patients with and without constipation. Compared to healthy controls (35:55, h:min), whole‐gut transit was slower in both diabetes patients with constipation (66:15, p = 0.03) and without constipation (71:16, p < 0.001). Small bowel motility index correlated rs = −0.32 (p = 0.01) with constipation symptoms.Conclusions: Diabetes patients with constipation had similar transit times as those without constipation. Both groups had slower whole‐gut transit than healthy controls. Constipation was associated with reduced small bowel, but not colonic contractility. Our results imply that other mechanisms than slow colonic transit may be more important in the pathogenesis of diabetic constipation.

17 September 2013 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
DLDina Lelic
Dina Lelic
CBChristina Brock
Christina Brock
MSMagnus Simrén
Magnus Simrén
JFJ. B. Frøkjaer
J. B. Frøkjaer
ESEirik Søfteland
Eirik Søfteland
ADAsbjørn M. Drewes
Asbjørn M. Drewes